Ischemic Stroke Clinical Trial
Official title:
Clinical Trial of Normobaric Oxygen Therapy in Acute Ischemic Stroke
The purpose of this study is to compare the safety and efficacy of treating individuals with acute ischemic stroke with normobaric oxygen therapy (NBO, given within 9 hours of symptom onset), to standard medical treatment.
Stroke is the third leading cause of death and the leading cause of disability in the United
States. Ischemic stroke is caused by a blockage of blood flow to one or more brain arteries,
usually due to a blood clot. As a result there is a reduced supply of oxygen and other
nutrients leading to permanent brain damage. Normobaric oxygen therapy (NBO, or high-flow
oxygen delivered via a facemask) shows promise as a simple, widely accessible, low-cost
therapy that can prevent stroke-related brain damage and extend the time window for
administering the clot-busting drug t-PA (tissue plasminogen activator), which is the only
acute stroke treatment approved by the Food and Drug Administration.
The primary goal of this trial is to compare the safety and therapeutic efficacy of NBO
(started within 9 hours of symptom onset) to standard medical treatment with Room Air. We aim
to enroll a total of 240 individuals with acute ischemic stroke less than 9 hours after
symptom onset, at the Massachusetts General and Brigham and Women's Hospitals in Boston.
Participants will be randomly selected to receive either room air (RA, control) or NBO
(active treatment) at flow rates of 30-45L/min administered via a face mask for 8 hours.
Neurological function scores and neuroimaging [magnetic resonance imaging (MRI) or computed
tomography (CT) scans] will be obtained before, during, and after therapy until 90 days.
This study is part of the Specialized Program of Translational Research in Acute Stroke
(SPOTRIAS), which allows researchers to enhance and initiate translational research that
ultimately will benefit individuals with stroke.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A |